JPMorgan: Moderna interim trial reaches primary endpoint, but success in adjuvant melanoma has already been priced into the market.
TechFlow reports, according to Chaoxiang Research, that JPMorgan's August 19 research report states Moderna's individualized neoantigen therapy (INT) in collaboration with Merck has met its primary endpoint of recurrence-free survival in the phase III trial for adjuvant melanoma, with the key secondary endpoint of distant metastasis-free survival also achieved. JPMorgan previously assigned an 85% success probability to this trial, viewing the results as in line with expectations, and noted the market had already priced this in ahead of the announcement. Moderna's premarket stock rose, while JPMorgan maintained an Underweight rating and a $40 price target, reflecting a 36% downside from the current $63.
JPMorgan believes the adjuvant melanoma indication contributes only around 3% to valuation, and data from INT in non-melanoma indications remains the critical variable affecting valuation. The current valuation model already incorporates approximately $15 per share in potential value for other indications. JPMorgan's price target is based on a DCF model, applying a weighted average cost of capital of 10.5% and a terminal growth rate of 0%.





